The precision health operating system
Quelm integrates pharmacogenomics, metabolic intelligence, cardiac safety, and AI coaching into a single HIPAA-compliant platform — protected by a layered IP strategy: 9 provisional filings, 9 in active pipeline, and 8 trade secret designations.
Why now
Four converging trends have opened a window that did not exist three years ago.
Consumer Biometrics at Scale
CGMs, wearables, and genetic testing kits have crossed the consumer adoption threshold. The raw data now exists — but no platform integrates it into clinical-grade decisions.
Genomics Cost Collapse
Whole-genome sequencing costs fell below $200. Pharmacogenomic panels are now economically viable for preventive care, not just oncology.
AI-Native Clinical Workflows
Large language models and on-device inference make personalized health coaching feasible without centralized PHI exposure.
Privacy Backlash
Consumers and regulators are rejecting ad-tech approaches to health data. The market demands privacy-first architectures — our founding constraint.
What we've built
A production-grade precision health platform — not a prototype.
6 Innovation Domains
Moat architecture
Four interlocking moats — each reinforcing the others.
IP Moat
9 provisional filings (Tier 1), 9 in 6-month pipeline (Tier 2), 8 trade secret protections (Tier 3). 350+ claims across 6 domains.
Data Moat
Multi-omics integration (genomics, metabolomics, microbiome, cardiac, behavioral) creates compound data advantage. Each patient generates cross-domain signal no competitor can replicate from a single data source.
Workflow Moat
Pre-screening qualification, cardiac safety gating, and clinician override rails are deeply embedded in the treatment flow. Switching cost is clinical-process-level, not software-license-level.
Trust Moat
HIPAA-compliant from day one. Federated learning means models improve without centralizing PHI. On-device inference via ONNX. Patients own their data.
Revenue model
Direct-to-Consumer
Tiered subscription: Basic (biomarker tracking + AI coaching), Pro (pharmacogenomics + digital twin), Premium (full multi-omics integration).
Clinical Licensing
Clinician dashboard for patient monitoring, treatment protocol management, and outcome tracking. White-label available for health systems.
Research Data Partnerships
De-identified, federated insights for pharmaceutical R&D, clinical trials recruitment, and population health research. Zero raw data leaves the device.
Growth Trajectory
ProjectedExecution timeline
Core platform built: 385K LOC, 82 tables, 9 clinical engines, HIPAA infrastructure.
9 provisional specifications filed. 9 additional innovations in filing pipeline. 8 protected as trade secrets. 350+ claims across portfolio. $295K+ invested.
Seed raise. Founding cohort waitlist. Clinical advisory board formation.
Controlled pilot with 100-500 patients. Partner clinic onboarding. IRB submission.
Series A raise. Observational study data. Clinical licensing launch.
FDA 510(k) pathway for clinical decision support. Prospective clinical trial. 10K+ patients.
Use of Funds
Request investor materials
Request access to the investor deck, product brief, IP portfolio summary, and execution roadmap.